Telomir Pharmaceuticals, Inc.
TELO
$1.22
$0.032.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.32M | 573.50K | 838.50K | 387.00K | 5.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.76M | 1.04M | 2.13M | 1.15M | 5.07M |
| Operating Income | -1.76M | -1.04M | -2.13M | -1.15M | -5.07M |
| Income Before Tax | -1.72M | -990.90K | -2.06M | -1.10M | -5.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.72M | -990.90K | -2.06M | -1.10M | -5.07M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.72M | -990.90K | -2.06M | -1.10M | -5.07M |
| EBIT | -1.76M | -1.04M | -2.13M | -1.15M | -5.07M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.79 | -0.03 | -0.06 | -0.03 | -0.17 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.04 | -0.02 | -0.11 |
| EPS Diluted | -0.79 | -0.03 | -0.06 | -0.03 | -0.17 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.04 | -0.02 | -0.11 |
| Average Basic Shares Outstanding | 60.84M | 34.38M | 33.49M | 32.40M | 30.01M |
| Average Diluted Shares Outstanding | 60.84M | 34.38M | 33.49M | 32.40M | 30.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |